The utilization of umbilical cord blood (UCB) as a source of stem cells for transplantation has grown substantially in the last decade. Already an established practice for the treatment of children with hematological malignancies, its application for the treatment of adults is also expanding. The development of the double UCB and reduced-intensity transplantation platforms have contributed to this expansion. Recent registry-based analysis and ongoing single institution and multicenter clinical trials are investigating ways to make UCB transplantation more widely available. We review here the background data on the utilization of UCB for the treatment of hematological malignancies, and discuss the current challenges and future directions in the field of UCB transplantation.
Introduction
The role of umbilical cord blood (UCB) transplantation in the treatment of hematological malignancies has grown substantially in the last several years. This expansion has been largely driven by the need for alternative sources of hematopoietic stem cells (HSCs) for transplantation as, despite 10 million donors being registered worldwide, only about a third of the patients are able to identify a suitable and available HLA-matched unrelated adult donor (MUD) according to the National Marrow Donor Program (Personal communication from Roberta King, National Marrow Donor Program, United States). However, the success in finding an MUD depends on the ethnic background of the recipient. 1 In addition, the search for an MUD may take as long as 3-4 months, which may be an issue for patients with high-risk aggressive malignancy.
As discussed elsewhere in this supplement, the importance of UCB as a source of HSCs for patients with hematological malignancies includes: (1) less strict HLAmatching criteria often yielding several suitable UCB units despite no available MUD, and (2) UCB is rapidly available for limiting delay in patients with high-risk aggressive diseases, thus reducing the time for disease relapse and the need for additional toxic therapy. We will discuss growing evidence that shows that UCB is an important alternative source of HSCs for transplantation and its implications for the future utilization of UCB grafts in oncology.
UCB transplantation in children with malignancies
Early reports of UCB transplantation mostly reflected the outcomes of pediatric patients, largely because of the limitation in cell dose available from a single UCB unit. The early encouraging results led to significant growth of experience with UCB transplantation in children. [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] Studies comparing UCB with adult donor HSCs show that outcomes are similar, suggesting an important role for UCB as a source of stem cells in this patient population. 8, 9, [12] [13] [14] In children, where UCB units with cell doses of 2.0 Â 10 7 /kg at cryopreservation are frequently found, engraftment has been consistently above 90% despite the number of nucleated or CD34 þ cells being about 1 log lower than in adult donor grafts. 15 The incidence of acute GVHD after UCB transplantation is low compared with that of adult HSC grafts, despite the consideration that most UCB grafts are mismatched. 8, 9, [12] [13] [14] 16 The reduced incidence of GVHD has been attributed to the naivete´of the neonatal immune system. This apparently reduced alloreactivity, however, does not compromise long-term risks of relapse. In studies comparing UCB with adult HSC grafts in the pediatric setting, relapse rates after UCB transplantation range from 15 to 40% and survival from 40 to 60% (Table 1 ). In the most recent and largest registrybased comparative study in the pediatric setting, Eapen et al.
14 compared 7 or 8/8 HLA-matched unrelated donors (allele level matched HLA A, B, C and DRB1) with 4-6/6 HLA-matched UCB (Ag level for HLA A and B, and allele level for DRB1). An interesting finding in this report was that better matched grafts had better engraftment and lower treatment-related mortality (TRM), but higher relapse rates, whereas the opposite was observed with less well-matched grafts. This resulted in comparable leukemiafree survival for all studied subgroups, except for superior outcomes in the 6/6 HLA-matched UCB recipients who had an leukemia-free survival nearing 60% (Figure 1) . The outcomes of patients who received larger 5/6 HLAmatched UCB units with a cryopreserved cell dose 43 Â 10 7 /kg were similar to 8/8 MUD BM. In contrast, patients who received a 1-Ag mismatched UCB unit with a smaller cryopreserved cell dose of p3 Â 10 7 /kg had inferior outcomes compared with MUD BM, yet similar to those who received 2-Ag mismatched units.
14 This confirms earlier observations that increasing the UCB cell dose can, at least in part, compensate for HLA mismatch. 15 The ability to find suitably sized and HLA-matched UCB units allow UCB transplantation to become common practice for the treatment of children with hematological malignancies. In many centers, UCB has become the preferred source of unrelated HSCs for transplantation. It is expected that the indications of UCB for the treatment of children with malignancies will continue to grow. Large multicenter studies, such as the Bone Marrow Transplantation-Clinical Trials Network (BMT-CTN) Study 0501 that is testing a randomized comparison of one or two UCB units for children with leukemia, are likely to contribute to this growth. Future areas of research initiatives will likely include understanding: (1) the out- comes of individual leukemia subtypes (AML and ALL); (2) optimal conditioning regimens for defined populations; (3) comparing the role of fludarabine vs anti-thymocyte globulin as adjunct immune suppressors; and (4) patterns of immunological reconstitution, infection and recovery after UCB grafting.
UCB transplantation in adults with malignancies
The experience with UCB transplantation for the treatment of adults with hematological malignancies has grown much more slowly than in children. The main limiting factor has been the available cell doses from a single UCB unit. This topic is reviewed in detail elsewhere in this supplement. Early studies, including only a small number of adults, reported that larger patients were more likely to receive UCB units providing a lower cell dose per kg and greater mismatch (X2 HLA-mismatches) leading to a higher probability of adverse events. 11 In addition, the significantly longer interval from diagnosis to UCB transplantation compared with unrelated adult donor grafts 17 suggests that patients were often referred for UCB transplantation as a last resort once a prolonged MUD search had been unsuccessful. Consequently, adult patients undergoing UCB transplantation had more advanced disease or were more heavily pretreated. Laughlin et al. 18 reported the first series of adults receiving UCB transplantation after myeloablative conditioning, mostly for hematological malignancies (54 of 68 patients).
More recently, registry and single institution analyses have compared the outcomes after UCB and adult donor grafts from related and unrelated donors ( Table 2) . Two large registry studies compared the outcomes of adults with leukemia undergoing UCB or unrelated donor BMT after Cord blood for oncology CG Brunstein and DJ Weisdorf myeloablative conditioning. 17, 19 In these analysis, patients had HLA-A and -B typing at the Ag level and DRB1 at the allele level, and leukemia-free survival was similar for recipients of UCB and unrelated donor BM (Figures 2  and 3 ). An important new study in adult patients with leukemia compared UCB with unrelated adult donors with combined data from the Center for International Blood and Marrow Transplant Research (CIBMTR) and Eurocord registries. 20 As recently presented at the 2008 Meeting of the American Society of Hematology, the authors compared the outcomes of 4-6/6 HLA-matched UCB and 7-8/8 allele MUDs. This study showed superior outcomes for 8/8 allele-matched HLA BM and peripheral blood grafts, whereas the outcomes of UCB and 1-locus mismatched BM and peripheral blood were similar. These studies support the utilization of UCB as an alternative source of HSCs for patients with no HLA-matched unrelated donor.
Single institution comparisons between UCB and adult donor stem cell sources have also been reported ( Table 2) . Takahashi et al. 21 studied patients with hematological malignancies who receive either 3-6/6 HLA-matched UCB or 5-6/6 HLA-MUD grafts. In contrast to the registrybased studies, they observed a lower risk of TRM and better disease-free survival after UCB transplantation. More recently, the same group reported a comparative analysis between UCB and related donor BM or peripheral blood grafts in adults with hematological malignancies (Table 2) . 22 The incidence of grade II-IV GVHD was the same, but the incidence of severe acute and extensive chronic GVHD was lower in recipients of UCB grafts. TRM, relapse and disease-free survival were similar for the two HSC sources. At the University of Minnesota, Kumar et al. 23 compared the outcomes of ALL patients who received an UCB, matched related donor, MUD or mismatched URD after myeloablative conditioning. In this series, there were significant differences among the stem cell sources regarding the year of transplantation, conditioning regimens, time from diagnosis to transplantation and, as expected, cell doses infused. In multivariate analysis, poorer leukemia-free survival was associated with a mismatched URD graft, as well as with advanced disease (XCR3), white cell count X30 Â 10 9 /l at diagnosis, CMV seropositive recipient or donor, and taking X2 induction cycles to achieve a CR. UCB outcomes, however, were similar to or better than matched related and unrelated grafts. By offering UCB transplantation to patients with earlier disease stages and homogeneity of patient management because of our center's UCB transplant experience, patient selection may explain the promising results in contrast registry reports.
As time to neutrophil recovery is still an important barrier to UCB transplantation, particular for adults, several groups have been investigating strategies to shorten it. Recently reported studies have investigated the intra-BM injection (IBMI) of UCB grafts. 24, 25 The rationale for these studies was to enhance neutrophil recovery by delivering the HSCs directly into the BM space, thus reducing the systemic 'wasting' of an already limited number of progenitors. Frassoni et al. 25 reported on the IBMI in the setting of UCB transplantation with one unit, whereas our group studied this technique in the setting of two UCB units. 24, 25 Frassoni et al. 25 observed consistent engraftment and a reduced incidence of acute GVHD, but all patients received anti-thymocyte globulin, which may have favorably influenced the risks of GVHD. Nevertheless, considering the cell doses infused, their results with this IBMI approach were encouraging. Larger numbers of patients and more uniform management in the context of prospective clinical trial may be warranted to validate the findings in the single UCB setting. In our study, 24 we randomly assigned one of the UCB units to be delivered by IBMI, whereas the other was infused intravenously. We hypothesized that the procedure would be safe and that the IBMI unit would have a repopulating advantage. However, after treating 10 eligible patients, we closed our study on the basis of projected statistical futility, as the median time to neutrophil was similar to our historical controls and the IBMI was predominating only half of the time. Both studies showed that IBMI is feasible and safe, but its role in UCB transplantation is yet to be determined.
Other strategies to shorten the time to neutrophil recovery involve the utilization of highly purified committed hematopoietic progenitors from haploidentical or third party unrelated donors and studies of UCB ex vivo expansion. Fernandez et al. [26] [27] [28] reported the co-infusion of large numbers of highly purified CD34 þ progenitors from haploidentical donors in the setting of myeloablative transplantation with one UCB unit. The median time to neutrophil recovery was 10 days. Although haploidentical cells were detected in early time points, long-term hematopoiesis was derived from the UCB grafts. Our group is starting a phase I clinical trial of co-infusing highly purified CD34 þ hematopoietic progenitors from unrelated donors with single and double UCB grafts after myeloablation. Although the HLA matching of the donor of the purified progenitors is known, no HLA matching will be required for their use. Similar to Fernandez et al., 28 the goal is to shorten the time to neutrophil recovery, potentially reducing the incidence of infectious complications. Ex vivo expansion continues to be an actively investigated strategy. [29] [30] [31] One of the most promising approaches is the utilization of cocultures of UCB-derived CD34 þ CD38À precursors with the immobilized Notch1 ligand. 31 In an ongoing clinical trial in the myeloablative setting, patients receive two UCB units. One of the two units is ex vivo expanded and is co-infused with a second unit that is unmanipulated. 30 The relative contribution of each unit to the patients' hematopoietic reconstitution can be followed by chimerism studies. Early results are encouraging with a median time to neutrophil recovery of 14 days (range, 7-34). Once completed, this trial may bring new insights regarding ex vivo expansion and its potential in UCB transplantation. Another interesting area of future investigation involves the utilization of reagents that enhance HSC homing, such as diprotin A 32, 33 and C 0 fragment 3a. [34] [35] [36] Both reagents have been shown in murine models to enhance homing through SDF1-mediated mechanisms.
UCB reduced-intensity conditioning transplantation
The development of reduced-intensity conditioning (RIC) regimens allowed for the treatment of older patients and those with associated comorbid conditions. In fact, the median age of onset for most hematological malignancies is in the fifth and sixth decades of life 37 when myeloablative conditioning is associated with higher morbidity and mortality. These older patients make up a large population of patients with hematological malignancies who would potentially benefit from RIC UCB transplantation strategies, and this is reflected in the growing number of publications in the area. [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] Outcomes after RIC UCB transplantation have been encouraging, with most patients achieving prompt neutrophil recovery and donor chimerism plus promising PFS and OS (Table 3 ). There is variability in the incidence of acute (10-60%) and chronic (10-40%) GVHD, which may be related to differences in the conditioning regimen, post transplantation immunosuppression, and the number of UCB units composing the graft and ethnic heterogeneity of the study population. There is also a wide range of TRM (10-60%), likely reflecting differences in patient selection and center expertise. At the University of Minnesota, we have performed over 250 RIC UCB transplants, and in a report on the first 110 patients with hematological malignancies who were conditioned with CY, fludarabine and 200 cGy TBI, we observed a median time to neutrophil recovery Table 3 Reduced-intensity conditioning and UCB transplantation Abbrerviations: ATG ¼ anti-thymocyte globulin; aGVHD ¼ acute GVHD; cGVHD ¼ chronic GVHD; DFS ¼ disease-free survival; Flu ¼ fludarabine; NA ¼ not applicable or not available; pts ¼ patients; TRM ¼ treatment-related mortality; UCB ¼ umbilical cord blood. a Three patient also received low dose MTX days 3 (10 mg/m 2 ) and 6 (7 mg/m 2 ). b Pediatric series that includes malignant (n ¼ 14) and non-malignant diseases (n ¼ 7). c Four patients received BU instead of melphalan; one patient had thiotepa (5 mg/kg) added to the conditioning regimen. of 12 days, as well as incidence of grade II-IV acute GVHD of 59%, of grade III-IV of 22% and TRM at 3 years of 26%. At 3 years, the EFS was 38% and OS was 45%. 38 The Boston group has had similarly encouraging data, in particular regarding the utilization of a tacrolimus and sirolimus post transplantation immunosuppression regimen. 40, 41 Although the target population of myeloablative conditioning and UCB transplantation is largely acute leukemia, RIC regimen candidates more frequently have lymphoid malignancies. Recent reports are providing the first insights into disease-specific outcomes for this disease group. 47, [54] [55] [56] [57] The reported PFS for patients with intermediate and low grade lymphoid malignancies ranges from 20 to 50%. Comparisons between recipients of UCB and related PBSC grafts who were either X55 years 58 or who had AML 55 found similar outcomes using either graft source. The BMT-CTN study is conducting a prospective multicenter Phase II study of RIC UCB transplantation (Protocol 0604) for patients with hematological malignancies to confirm the encouraging results of these single center experiences. In this study, all patients will receive double UCB grafts after a CY/fludarabine/TBI-200 cGy conditioning. Immunosuppression will include CYA and mycophenolate mofetil. The study's target accrual is 50 patients with high-risk hematological malignancies and it should be completed in 2-3 years. This study is being run in parallel with a phase II reduced-intensity haploidentical transplant trial (CTN 0603) with the same eligibility criteria. The results of these two phase II studies may lead to a future randomized trial.
Double UCB transplantation
The double UCB transplant platform (Figure 4) , initially developed at the University of Minnesota, was designed to overcome the cell dose limitation preventing most adults from receiving a UCB graft. 38, 39, 59, 60 There is growing interest on investigating this strategy for the treatment of adult patients with hematological malignancies in both the myeloablative conditioning and RIC settings. 29, 40, 41, 56, [61] [62] [63] [64] In the myeloablative setting, double cord transplantation for adults has been shown to produce reproducible engraftment, low TRM and PFS similar to other stem cell sources. 56, 59, 62, 63, 65 Similar observations have been made in the reduced-intensity setting. 40, 41, 56 Patients with acute leukemia in CR receiving a two UCB have a lower relapse risk compared with those who received one UCB unit. 66 This observation has now been reproduced. 56, 63 However, this enhanced alloreactivity and reduced relapse risk have also been associated with an increased incidence of acute GVHD, 67 though the excess risk was primarily grade II skin GVHD. Grade III-IV acute GVHD is not increased after double UCB grafting. The double UCB platform is now serving as the backbone to investigate newer strategies to improve engraftment and outcomes. 29, 30 It is being explored in numerous single institution and multicenter clinical trials, including BMT-CTN 0501, which is randomizing one vs two UCB unit grafts for children with leukemia receiving myeloablative conditioning.
Future directions
The utilization of UCB grafts to treat patients with malignancies is growing and is increasingly successful. UCB transplantation is routinely offered to children with leukemia with expected results similar to MUD allografts. The double UCB platform and the utilization of RIC have expanded UCB transplantation to adults and to older sicker patients unable to tolerate myeloablative conditioning. The growing number of patients receiving UCB transplantation will help us address several open questions such as: How to choose the best UCB unit? Are there patients for whom we should prefer UCB over MUD or partially matched donors? Are there diseases or disease stages for which we should prefer UCB over MUD or partially matched donors? How should the presence of comorbid conditions influence our choice of conditioning regimen? The availability of disease-specific outcomes will help us counsel our patients in making these choices. The results of ongoing prospective clinical trials will improve the understanding of the indications and applicability of double UCB grafts and RIC UCB transplantation. Interesting recent modifications such as IBMI of UCB need validation in more patients and other centers. 25 The impact of KIR ligand matching or other genetic elements pertinent for donor selection on the outcomes of UCB transplantation remains controversial. A study reported by Willenze et al. 68 suggests reduced relapse risk and improved survival for patients with leukemia who received a single UCB unit that KIR-L mismatched in the GVHD direction. In contrast, our data from the University of Minnesota observed no difference in outcomes in the myeloablative setting, whereas in the RIC setting, KIR-L mismatch led to significantly higher risk of acute GVHD, TRM and poorer survival and without impact on relapse risk. 69 The field of UCB transplantation is now moving at a faster pace for both children and adults. Transplant centers will no longer look at UCB as a last resort in seeking a graft and will start offering UCB transplantation for patients with high-risk disease in earlier stages of their illness. Searches for unrelated donors that are likely to be unsuccessful will be abandoned sooner in favor of UCB. A larger worldwide inventory of high quality UCB units will allow finding larger and better matched units.
In addition to the multiple new strategies to improve the outcomes of UCB transplantation discussed here, one must also consider the optimization of conditioning and immunosuppression regimens by substituting or eliminating drugs that delay immune reconstitution and increase the risk of opportunistic infections such as anti-thymocyte globulin and steroids. One approach may involve the manipulation of the T-cell content by either adding or inducing the expansion of regulatory T cells.
Umbilical cord blood-derived HSCs have great promise for modification and improvement in allogeneic transplantation. They have vast proliferative potential and intrinsically greater immunologic tolerance yet potent capacity for both innate and acquired immunologic reconstitution. Further study of this potent cell population offers great opportunity to rapidly provide suitable allografts for nearly all patients, particularly those from ethnic and racial minorities who remain poorly served by volunteer donor registries where very close HLA matching is critical. Imaginative future research will likely amplify the broad applicability of these cells and help even greater numbers of future patients.
